A prospective study of patients undergoing trabecular micro-bypass implantation with iStent or iStent inject® at the time of cataract surgery shows clinically and statistically significant improvements in ocular surface disease (OSD), including tear break-up time, corneal/conjunctival staining, and Ocular Surface Disease Index scores (OSDI).